Phase 4
Completed N=65
Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD)
Source: ClinicalTrials.gov NCT00700999 ↗Enrolled (actual)
65
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcomePrimary: Percent Change in Brain Response Measured by Functional Magnetic Resonance Imaging (fMRI) — -.92; .07 percent change in BOLD signal — p=.001
Summary
The purpose of this study is to examine if treatment of post-traumatic stress disorder in combat veterans with paroxetine changes brain responses as measured by functional magnetic resonance imaging and if brain responses can predict who will get better with treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in Brain Response Measured by Functional Magnetic Resonance Imaging (fMRI) |
-.92; .07 | .001 sig |
Eligibility Criteria
Inclusion Criteria
- Veterans with clinical diagnosis of post-traumatic stress disorder from combat related to deployment to Afghanistan/Iraq (Operation Enduring Freedom/Operation Iraqi Freedom)
Exclusion Criteria
- Intolerance or sensitivity to paroxetine
- Major medical or neurologic illness
- Current psychotropic medication or active psychotherapy treatment
- Other major psychiatric illness
Data sourced from ClinicalTrials.gov (NCT00700999). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.